Otonomy, Inc.
6275 Nancy Ridge Drive
Suite 100
San Diego
California
92121
United States
Tel: 858-242-5200
Fax: 858-200-0933
Website: http://www.otonomy.com/
Email: info@otonomy.com
About Otonomy, Inc.
Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to address diseases of the inner and middle ear. There are no drugs currently approved by the FDA for the lead indications we are currently pursuing for our product candidates. Our lead candidate AuriPro completed Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery, and we have submitted a request to the FDA for approval. If approved, we anticipate a commercial launch in early 2016 and are building our business and commercial team to meet the needs of this next stage of our growth.
127 articles with Otonomy, Inc.
-
Otonomy, Inc.'s OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
2/22/2011
-
Otonomy, Inc. Adds Key Product and Industry Experience with Appointment of New Vice Presidents
2/3/2011
-
Otonomy, Inc. Appoints David A. Weber, Ph.D., Chief Executive Officer
12/8/2010
-
Otonomy, Inc. Closes $38.5 Million Series B Financing
8/30/2010
-
Otonomy, Inc. Closes $10 Million Series A Financing
6/11/2010
-
Otonomy, Inc. Receives FDA Clearance to Initiate Clinical Trial in Patients with Meniere's Disease
2/17/2010
-
Otonomy, Inc. Introduces Scientific Advisory Board
3/30/2009